Research Progress of Antibody-Drug Conjugates in Ovarian Cancer

卵巢癌致死率高，是严重威胁女性生命健康的妇科恶性肿瘤，大多数晚期卵巢癌患者最终不可避免的进入铂耐药阶段。由于铂耐药患者对各种化疗的反应较差，预后欠佳，铂耐药卵巢癌的治疗面临着巨大的挑战。抗体偶联药物(Antibody-drug Conjugate, ADC)是由靶向特异性抗原的单克隆抗体与小分子细胞毒性药物通过连接子连接而成的一类药物，已在血液恶性肿瘤和乳腺癌、非小细胞肺癌等实体瘤中有了成熟的应用。随着FDA加速批准Mirvetuximab Soravtansine治疗铂耐药复发卵巢癌，ADC类药物在卵巢癌治疗中也有了更多的研究和应用。本文阐述了ADC在卵巢癌中的主要临床研究进展。 Ovarian cancer has a high mortality rate and is a serious threat to women’s health. Most patients with advanced ovarian cancer inevitably enter the platinum-resistant stage. Due to the poor response of platinum-resistant patients to various chemotherapies and poor prognosis, the treatment of platinum-resistant ovarian cancer faces huge challenges. Antibody-drug conjugates (ADCs) are a class of drugs composed of monoclonal antibodies targeting specific antigens and small molecule cytotoxic drugs linked by a linker. They have been successfully applied in hematological malignancies and solid tumors such as breast cancer and non-small cell lung cancer. With the FDA’s accelerated approval of Mirvetuximab Soravtansine for the treatment of platinum-resistant recurrent ovarian cancer, ADCs have also received more research and application in the treatment of ovarian cancer. This article elaborates on the main clinical research progress of ADCs in ovarian cancer.